RemedyBio
Remedy is creating a revolution in immune therapeutics though cell-by-cell analysis of immune and disease biology
Remedy is creating a revolution in immune therapeutics though cell-by-cell analysis of immune and disease biology
RemedyBio is a Dublin-based biotech company leveraging nanoscale technology to revolutionize immune therapeutics. Specializing in immuno-oncology, autoimmune diseases, and infectious diseases, the company's innovative approach involves the analysis of 10M-1Bn cells individually, significantly advancing single-cell research. Conducting combinational biology at scale, RemedyBio simultaneously analyzes healthy tissue, disease biology, and immunological function, providing a comprehensive understanding of diseases. Their advanced methodology involves statistical and machine analysis of millions or billions of cells, including those from patient tumor biopsies. Additionally, RemedyBio offers services for therapeutic design and long-term asset building, including sequencing, replicating, and banking post-assay biology. Established in 2017, the company recently secured a significant €8.00M Venture Round investment from The European Innovation Council on 20 July 2021.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | €8.00M | 1 |
|
20 Jul 2021 |
| Grant | €2.50M | 1 |
|
01 Jun 2020 |
No recent news or press coverage available for RemedyBio.
We care about your data, and we'd love to use cookies make your experience better.
